Inventiva in the Red: Shares Drop 10%, Support Broken
Inventiva experienced a significant decline on Tuesday, March 31, 2026, dropping 10.21% to €4.31 during the session, following the publication of its annual results for 2025 the previous day. The movement follows a downward trend that has intensified over the past several weeks, with a 17.37% decrease over seven days and a 21.13% decrease over a month. The French biotech is facing multiple negative signals simultaneously at a time when its financing visibility raises questions.
INVENTIVA published its annual results for 2025 on Monday, a milestone that coincides with this new weakness in the stock. The previous session had already ended with a decline, bringing the price down to €4.80, a level that has now been broken downwards this Tuesday morning. The publication highlights a concerning cash situation: according to our information, the company has €230 million in cash, but its financial autonomy does not exceed one year. For a biotech in the clinical development phase, this parameter is nevertheless closely monitored by investors. The finding fuels the selling pressure observed since the beginning of the month, in a market context already strained, with the VIX in an extreme stress zone at 31.05.
Technical Analysis and Market Comparison
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a chart perspective, the most notable signal of the session is the downward breach of the €4.80 support. This level had previously contained declines, and its abandonment opens a bearish path to lower price zones. The 50-day moving average, established at €5.34, is significantly distancing from the current price, confirming the deterioration of the medium-term trend. The RSI, at 36, is approaching the oversold threshold without yet reaching it. The technical configuration remains under pressure, with no established technical rebound signal at this stage. By comparison, benchmark pharmaceutical stocks are moving in the opposite direction this Tuesday: Sanofi is up 1.67% and UCB by 1.26%, highlighting the specific nature of the movement affecting Inventiva, independent of any sector dynamics. Over twelve months, the stock still shows a positive performance of 57.17%, which puts the recent losses into perspective in a longer-term view.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
